PMC:7441788 / 20204-20639 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T111","span":{"begin":192,"end":203},"obj":"Body_part"},{"id":"T112","span":{"begin":279,"end":290},"obj":"Body_part"}],"attributes":[{"id":"A111","pred":"fma_id","subj":"T111","obj":"http://purl.org/sig/ont/fma/fma54878"},{"id":"A112","pred":"fma_id","subj":"T112","obj":"http://purl.org/sig/ont/fma/fma54878"}],"text":"Gautret et al [58]. Observational study HCQ group: n = 80; no control HCQ, 200 mg/3 times/day for 10 days combined with azithromycin 500 mg on the 1st day, 250 mg/day afterward for 5 days The nasopharynx viral load in most patients received HCQ decreased rapidly. Observation of nasopharynx viral load. Observational study design and no control group; No clinical outcomes were analyzed. Possible confounding factors were not adjusted."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T10","span":{"begin":192,"end":203},"obj":"Body_part"},{"id":"T11","span":{"begin":279,"end":290},"obj":"Body_part"}],"attributes":[{"id":"A10","pred":"uberon_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/UBERON_0001728"},{"id":"A11","pred":"uberon_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/UBERON_0001728"}],"text":"Gautret et al [58]. Observational study HCQ group: n = 80; no control HCQ, 200 mg/3 times/day for 10 days combined with azithromycin 500 mg on the 1st day, 250 mg/day afterward for 5 days The nasopharynx viral load in most patients received HCQ decreased rapidly. Observation of nasopharynx viral load. Observational study design and no control group; No clinical outcomes were analyzed. Possible confounding factors were not adjusted."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T247","span":{"begin":44,"end":49},"obj":"Chemical"},{"id":"T248","span":{"begin":120,"end":132},"obj":"Chemical"},{"id":"T249","span":{"begin":345,"end":350},"obj":"Chemical"}],"attributes":[{"id":"A247","pred":"chebi_id","subj":"T247","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A248","pred":"chebi_id","subj":"T248","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A249","pred":"chebi_id","subj":"T249","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"Gautret et al [58]. Observational study HCQ group: n = 80; no control HCQ, 200 mg/3 times/day for 10 days combined with azithromycin 500 mg on the 1st day, 250 mg/day afterward for 5 days The nasopharynx viral load in most patients received HCQ decreased rapidly. Observation of nasopharynx viral load. Observational study design and no control group; No clinical outcomes were analyzed. Possible confounding factors were not adjusted."}

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T12","span":{"begin":204,"end":214},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"},{"id":"T13","span":{"begin":291,"end":301},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A13","pred":"meddra_id","subj":"T13","obj":"http://purl.bioontology.org/ontology/MEDDRA/10062178"},{"id":"A12","pred":"meddra_id","subj":"T12","obj":"http://purl.bioontology.org/ontology/MEDDRA/10062178"}],"text":"Gautret et al [58]. Observational study HCQ group: n = 80; no control HCQ, 200 mg/3 times/day for 10 days combined with azithromycin 500 mg on the 1st day, 250 mg/day afterward for 5 days The nasopharynx viral load in most patients received HCQ decreased rapidly. Observation of nasopharynx viral load. Observational study design and no control group; No clinical outcomes were analyzed. Possible confounding factors were not adjusted."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T139","span":{"begin":120,"end":132},"obj":"Chemical"}],"attributes":[{"id":"A139","pred":"chebi_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"}],"text":"Gautret et al [58]. Observational study HCQ group: n = 80; no control HCQ, 200 mg/3 times/day for 10 days combined with azithromycin 500 mg on the 1st day, 250 mg/day afterward for 5 days The nasopharynx viral load in most patients received HCQ decreased rapidly. Observation of nasopharynx viral load. Observational study design and no control group; No clinical outcomes were analyzed. Possible confounding factors were not adjusted."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T151","span":{"begin":0,"end":19},"obj":"Sentence"},{"id":"T152","span":{"begin":20,"end":263},"obj":"Sentence"},{"id":"T153","span":{"begin":264,"end":302},"obj":"Sentence"},{"id":"T154","span":{"begin":303,"end":387},"obj":"Sentence"},{"id":"T155","span":{"begin":388,"end":435},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Gautret et al [58]. Observational study HCQ group: n = 80; no control HCQ, 200 mg/3 times/day for 10 days combined with azithromycin 500 mg on the 1st day, 250 mg/day afterward for 5 days The nasopharynx viral load in most patients received HCQ decreased rapidly. Observation of nasopharynx viral load. Observational study design and no control group; No clinical outcomes were analyzed. Possible confounding factors were not adjusted."}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T9","span":{"begin":192,"end":203},"obj":"Body_part"},{"id":"T10","span":{"begin":279,"end":290},"obj":"Body_part"}],"attributes":[{"id":"A10","pred":"uberon_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/UBERON_0001728"},{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0001728"}],"text":"Gautret et al [58]. Observational study HCQ group: n = 80; no control HCQ, 200 mg/3 times/day for 10 days combined with azithromycin 500 mg on the 1st day, 250 mg/day afterward for 5 days The nasopharynx viral load in most patients received HCQ decreased rapidly. Observation of nasopharynx viral load. Observational study design and no control group; No clinical outcomes were analyzed. Possible confounding factors were not adjusted."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T110","span":{"begin":192,"end":203},"obj":"Body_part"},{"id":"T111","span":{"begin":279,"end":290},"obj":"Body_part"}],"attributes":[{"id":"A110","pred":"fma_id","subj":"T110","obj":"http://purl.org/sig/ont/fma/fma54878"},{"id":"A111","pred":"fma_id","subj":"T111","obj":"http://purl.org/sig/ont/fma/fma54878"}],"text":"Gautret et al [58]. Observational study HCQ group: n = 80; no control HCQ, 200 mg/3 times/day for 10 days combined with azithromycin 500 mg on the 1st day, 250 mg/day afterward for 5 days The nasopharynx viral load in most patients received HCQ decreased rapidly. Observation of nasopharynx viral load. Observational study design and no control group; No clinical outcomes were analyzed. Possible confounding factors were not adjusted."}

{"project":"LitCovid-sample-PD-MAT","denotations":[{"id":"T6","span":{"begin":192,"end":203},"obj":"http://purl.obolibrary.org/obo/MAT_0000447"},{"id":"T7","span":{"begin":279,"end":290},"obj":"http://purl.obolibrary.org/obo/MAT_0000447"}],"text":"Gautret et al [58]. Observational study HCQ group: n = 80; no control HCQ, 200 mg/3 times/day for 10 days combined with azithromycin 500 mg on the 1st day, 250 mg/day afterward for 5 days The nasopharynx viral load in most patients received HCQ decreased rapidly. Observation of nasopharynx viral load. Observational study design and no control group; No clinical outcomes were analyzed. Possible confounding factors were not adjusted."}

{"project":"LitCovid-sentences","denotations":[{"id":"T151","span":{"begin":0,"end":19},"obj":"Sentence"},{"id":"T152","span":{"begin":20,"end":263},"obj":"Sentence"},{"id":"T153","span":{"begin":264,"end":302},"obj":"Sentence"},{"id":"T154","span":{"begin":303,"end":387},"obj":"Sentence"},{"id":"T155","span":{"begin":388,"end":435},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Gautret et al [58]. Observational study HCQ group: n = 80; no control HCQ, 200 mg/3 times/day for 10 days combined with azithromycin 500 mg on the 1st day, 250 mg/day afterward for 5 days The nasopharynx viral load in most patients received HCQ decreased rapidly. Observation of nasopharynx viral load. Observational study design and no control group; No clinical outcomes were analyzed. Possible confounding factors were not adjusted."}